EPEva Prida

Eva Prida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eva Prida has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Mar Quiñones

    CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Av Monforte de Lemos 3-5, 28029 Madrid, Spain; Grupo Fisiopatología Endocrina, Área de Endocrinología, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complexo Hospitalario Universitario de Santiago (SERGAS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Galicia, Spain

    4 shared publications
  • Omar Al-Massadi

    Translational Endocrinology Group, Endocrinology Section, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)/Complexo Hospitalario Universitario de Santiago (SERGAS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Galicia, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Av Monforte de Lemos 3-5, 28029 Madrid, Spain

    4 shared publications
  • Luisa Maria Seoane

    Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain

    3 shared publications
  • Johan Fernø

    Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway

    2 shared publications
  • Raquel Perez-Lois

    Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (CHUS/SERGAS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain

    2 shared publications
  • Adrián Fernández Marcos

    Translational Endocrinology Group, Endocrinology Section, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo Hospitalario Universitario de Santiago (IDIS/CHUS), Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain

    1 shared publication

Latest Publications

  • Open Access

    Protocol for the injection of adenoviruses into brown adipose tissue in mice

    by Eva Prida, José Adrián Vázquez-Durán, Diego Muñoz-Moreno, Laura Díaz-Garzón, Ana María Torres Caldas, Luisa María Seoane, Mar Quiñones, María Pardo, Omar Al-Massadi

  • Open Access

    Hepatic Olfr734 Deficiency Worsens Hepatic Glucose Metabolism and Induces MASLD in Mice

    by Eva Prida, Diego Muñoz-Moreno, Eva Novoa, Tamara Parracho, Laura Diaz-Garzón Dopico, Raquel Perez-Lois, Miguel Bascoy-Otero, Ana Senra, Sergio Romero-Rodriguez, Beatriz Brea-García, et al.

    Background/Objectives: Asprosin is the endogenous ligand of the olfactory Olfr734 receptor linked to MASLD and glucose metabolism. Despite the involvement of asprosin in these processes, little has been published on the specific role of Olfr734 in liver function. The aim of this work is therefore to study the specific role of the olfactory Olfr734 receptor in MASLD and glucose metabolism. Methods: To achieve this objective, we performed a genetic inhibition specifically to inhibit Olfr734 in the livers of male mice. We then studied the progression of MASLD in DIO mice. In addition, we studied the glucose metabolism in hypoglycemia states and postprandial glucose production in standard diet-fed mice. Finally, analyses of liver biopsies from patients with obesity and with or without T2DM were conducted. Results: We found that hepatic Olfr734 levels vary according to changes in nutritional status and its knockdown effect in the liver is to increase the hepatic lipid content in DIO mice. Our results also showed that OLFR734 expression is involved in the adaptive response in terms of glucose production to nutrient availability. Finally, the hepatic human Olfr734 ortholog named OR4M1 has been observed to be at significantly higher levels in male patients with T2DM. Conclusions: This study increases understanding of the mechanisms by which the modulation of Olfr734 expression affects liver function.


  • Open Access

    Liver Brain Interactions: Focus on FGF21 a Systematic Review

    by Eva Prida, Sara Álvarez-Delgado, Raquel Pérez-Lois, Mateo Soto-Tielas, Ana Estany-Gestal, Johan Fernø, Luisa María Seoane, Mar Quiñones, Omar Al-Massadi

    Fibroblast growth factor 21 is a pleiotropic hormone secreted mainly by the liver in response to metabolic and nutritional challenges. Physiologically, fibroblast growth factor 21 plays a key role in mediating the metabolic responses to fasting or starvation and acts as an important regulator of energy homeostasis, glucose and lipid metabolism, and insulin sensitivity, in part by its direct action on the central nervous system. Accordingly, pharmacological recombinant fibroblast growth factor 21 therapies have been shown to counteract obesity and its related metabolic disorders in both rodents and nonhuman primates. In this systematic review, we discuss how fibroblast growth factor 21 regulates metabolism and its interactions with the central nervous system. In addition, we also state our vision for possible therapeutic uses of this hepatic-brain axis.


  • Open Access

    Crosstalk between Melanin Concentrating Hormone and Endocrine Factors: Implications for Obesity

    by Eva Prida, Sara Fernández-González, Verónica Pena-León, Raquel Pérez-Lois, Johan Fernø, Luisa María Seoane, Mar Quiñones, Omar Al Massadi

    Melanin-concentrating hormone (MCH) is a 19aa cyclic peptide exclusively expressed in the lateral hypothalamic area, which is an area of the brain involved in a large number of physiological functions and vital processes such as nutrient sensing, food intake, sleep-wake arousal, memory formation, and reproduction. However, the role of the lateral hypothalamic area in metabolic regulation stands out as the most relevant function. MCH regulates energy balance and glucose homeostasis by controlling food intake and peripheral lipid metabolism, energy expenditure, locomotor activity and brown adipose tissue thermogenesis. However, the MCH control of energy balance is a complex mechanism that involves the interaction of several neuroendocrine systems. The aim of the present work is to describe the current knowledge of the crosstalk of MCH with different endocrine factors. We also provide our view about the possible use of melanin-concentrating hormone receptor antagonists for the treatment of metabolic complications. In light of the data provided here and based on its actions and function, we believe that the MCH system emerges as an important target for the treatment of obesity and its comorbidities.